Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGSWW) Gains from Investment Securities (2020 - 2025)

GeneDx Holdings has reported Gains from Investment Securities over the past 6 years, most recently at $180000.0 for Q4 2025.

  • Quarterly results put Gains from Investment Securities at $180000.0 for Q4 2025, up 102.08% from a year ago — trailing twelve months through Dec 2025 was $2.5 million (down 8.36% YoY), and the annual figure for FY2025 was $2.5 million, down 8.36%.
  • Gains from Investment Securities for Q4 2025 was $180000.0 at GeneDx Holdings, down from $3.4 million in the prior quarter.
  • Over the last five years, Gains from Investment Securities for WGSWW hit a ceiling of $125.9 million in Q4 2021 and a floor of -$56.0 million in Q3 2022.
  • Median Gains from Investment Securities over the past 5 years was $528000.0 (2024), compared with a mean of $10.6 million.
  • Peak annual rise in Gains from Investment Securities hit 1862.71% in 2024, while the deepest fall reached 1682.3% in 2024.
  • GeneDx Holdings' Gains from Investment Securities stood at $125.9 million in 2021, then crashed by 54.22% to $57.6 million in 2022, then crashed by 100.84% to -$486000.0 in 2023, then plummeted by 1682.3% to -$8.7 million in 2024, then surged by 102.08% to $180000.0 in 2025.
  • The last three reported values for Gains from Investment Securities were $180000.0 (Q4 2025), $3.4 million (Q3 2025), and -$1.7 million (Q2 2025) per Business Quant data.